Skip to main navigation Skip to search Skip to main content

Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review

  • Varut Lohsiriwat
  • , Parvez Sheikh
  • , Robert Bandolon
  • , Dong Lin Ren
  • , April Camilla Roslani
  • , Kassandra Schaible
  • , Andreas Freitag
  • , Monique Martin
  • , Pelin Yaltirik
  • , Philippe Godeberge
  • Saifee Hospital
  • Southern Philippines Medical Centre
  • Sun Yat-Sen University
  • University of Malaya
  • Evidera, USA
  • Evidera, United Kingdom
  • Servier
  • Clinique du Trocadéro

Research output: Contribution to journalReview articlepeer-review

29 Citations (Scopus)

Abstract

Introduction: Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. Methods: Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. Results: The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (n = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. Conclusion: The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. Graphical abstract: [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)117-132
Number of pages16
JournalAdvances in Therapy
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2023

Keywords

  • Hemorrhoids
  • MPFF
  • Phlebotonics
  • Recurrence
  • Risk factors

Fingerprint

Dive into the research topics of 'Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review'. Together they form a unique fingerprint.

Cite this